Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.63 |
| ▸ | CASP1 | P29466 | 1/20 | 0.63 |
| ▸ | CASP7 | P55210 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | NQO1 | P15559 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MGAM | O43451 | 1/20 | 0.51 |
| ▸ | SI | P14410 | 1/20 | 0.51 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.51 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.50 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2337790 | 0.84 | ALDH1A1 (0.50) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| SCHEMBL11334710 | 0.82 | RAB9A (0.68) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| SCHEMBL8629831 | 0.82 | KDM4E (0.54) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| Iodide SCHEMBL8114884 | 0.82 | ALDH1A1 (0.48) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| SCHEMBL3383138 | 0.79 | MAOA (0.64) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| SCHEMBL6648325 | 0.79 | GAA (0.56) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| SCHEMBL4696277 | 0.79 | MAOA (0.90) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| Xanthone SCHEMBL29358061 | 0.79 | MAOA (1.00) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| Xanthone SCHEMBL41161 | 0.79 | MAOA (1.00) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| Xanthone SCHEMBL29398266 | 0.79 | MAOA (1.00) | MAOAKDM4EALDH1A1GLACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113189214-B | Large yellow croaker proliferation and releasing molecular marker and screening method thereof | 宁波大学 | 2022-06-21 | — | — | CN | claimed |
| CN-113189214-A | Large yellow croaker proliferation and releasing molecular marker and screening method thereof based on liquid phase-tandem mass spectrometry technology | 宁波大学 | 2021-07-30 | — | — | CN | claimed |
| US-6251571-B1 | MIXTURE OF OXIDIZER, DYE AND HYDROXYLAMINE | E. I. DU PONT DE NEMOURS AND COMPANY | 2001-06-26 | — | — | US | claimed |
| EP-0334068-B1 | UV curable expoxy functional silicones | GEN ELECTRIC (US) | 1994-12-14 | — | — | EP | claimed |
| US-4977198-A | ONIUM SALT PHOTOCATALYSTS; CONTROLLED ESTERIFICATION OF EPOXY GROUPS | GENERAL ELECTRIC COMPANY (US) | 1990-12-11 | — | — | US | claimed |
| EP-0334068-A2 | UV curable expoxy functional silicones | GENERAL ELECTRIC COMPANY (US) | 1989-09-27 | — | — | EP | claimed |
| US-12193325-B2 | Nitrogen-containing heterocycles for use in OLEDs | MERCK PATENT GMBH (DE) | 2025-01-07 | — | — | US | disclosed |
| EP-3978491-B1 | NITROGEN-CONTAINING HETEROCYCLES FOR USE IN OLEDS | MERCK PATENT GMBH (DE) | 2024-01-31 | — | — | EP | disclosed |
| CN-113189214-B | Large yellow croaker proliferation and releasing molecular marker and screening method thereof | 宁波大学 | 2022-06-21 | — | — | CN | disclosed |
| EP-3978491-A1 | NITROGEN-CONTAINING HETEROCYCLES FOR USE IN OLEDS | Merck Patent GmbH (DE) | 2022-04-06 | — | — | EP | disclosed |
| EP-3978491-A1 | NITROGEN-CONTAINING HETEROCYCLES FOR USE IN OLEDS | Merck Patent GmbH (DE) | 2022-04-06 | — | — | EP | disclosed |
| EP-3548477-B1 | NITROGEN-CONTAINING HETEROCYCLES FOR USE IN OLEDS | MERCK PATENT GMBH (DE) | 2021-10-27 | — | — | EP | disclosed |
| EP-3548477-B1 | NITROGEN-CONTAINING HETEROCYCLES FOR USE IN OLEDS | MERCK PATENT GMBH (DE) | 2021-10-27 | — | — | EP | disclosed |
| WO-2009121033-A2 | SUBSTITUTED NITROGEN HETEROCYCLES AND SYNTHESIS AND USES THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-10-01 | — | — | WO | disclosed |
| US-6881765-B2 | Curable release agent and separator using same | TOAGOSEI CO., LTD. (JP) | 2005-04-19 | — | — | US | disclosed |
| US-20040180982-A1 | Curable release agent and separator using same | TOAGOSEI CO., LTD. | 2004-09-16 | — | — | US | disclosed |
| US-4902701-A | Tetrazolyl substituted tricyclic compounds and pharmacological compositions thereof | BURROUGHS WELCOME CO. (US) | 1990-02-20 | — | — | US | disclosed |
| EP-0093381-B1 | TRICYCLIC COMPOUNDS, PREPARATION, USE AND INTERMEDIATES | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-07-23 | — | — | EP | disclosed |
| EP-0093381-A1 | Tricyclic compounds, preparation, use and intermediates | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-11-09 | — | — | EP | disclosed |
| EP-0037604-A1 | Initiator system for radiation curable compositions, radiation curable compositions containing such an initiator system, a process for curing said compositions and products covered therewith | AKZO N.V. (NL) | 1981-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12193325-B2 | Nitrogen-containing heterocycles for use in OLEDs | CYCS, OCIAD2, OCIAD1 | MAOA 424/4885KDM4E 2972/4885ALDH1A1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.